Showing results (11-20 of 46) with videos related to
Sort By:
Pageof 5
Clinical Therapeutics|December 22, 2015
Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian ParticipantsDamayanthi Devineni, David Polidori, Christopher Curtin, et al.Diabetes, Obesity & Metabolism|January 18, 2018
Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozinDavid Polidori, Hiroaki Iijima, Maki Goda, et al.The Journal of Clinical Endocrinology and Metabolism|April 16, 2013
Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitusDavid Polidori, Sue Sha, Atalanta Ghosh, et al.Journal of Medicinal Chemistry|July 3, 2025
Strategies to Improve Pharmacokinetics of Hepatic Uptake Transporter SubstratesSarah M Glass, David Polidori, Kevin J Coe, et al.Nephron|April 22, 2015
Determination of the renal threshold for glucose excretion in Familial Renal GlucosuriaInês Aires, Marc Fila, David Polidori, et al.Diabetes|August 11, 2019
Lower Insulin Clearance Parallels a Reduced Insulin Sensitivity in Obese Youths and Is Associated With a Decline in β-Cell Function Over TimeAlfonso Galderisi, David Polidori, Ram Weiss, et al.Sensors (Basel, Switzerland)|January 23, 2024
GNSS Radio Frequency Interference Monitoring from LEO Satellites: An In-Laboratory PrototypeMicaela Troglia Gamba, Brendan David Polidori, Alex Minetto, et al.Diabetes|November 8, 2023
Role of Glycosuria in SGLT2 Inhibitor-Induced Cardiorenal Protection: A Mechanistic Analysis of the CREDENCE TrialEle Ferrannini, Anna Solini, Simona Baldi, et al.Diabetes Care|April 12, 2012
Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetesJulio Rosenstock, Naresh Aggarwal, David Polidori, et al.The Journal of Clinical Endocrinology and Metabolism|November 19, 2015
Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With CanagliflozinJohn P Bilezikian, Nelson B Watts, Keith Usiskin, et al.Pageof 5